Use of microRNAs in personalized medicine

Methods in Molecular Biology

Volumn 1107, Issue , 2014, Pages 311-325

  Avci, Çiǧir Biray ^a   Baran, Yusuf ^b  

^a EGE UNIVERSITY   (Turkey)

^b IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

Author keywords

miRNAs; Personalized medicine; Pharmacogenomics

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 155; MICRORNA 205; MICRORNA 34A; UNTRANSLATED RNA;

ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; DISEASE COURSE; DRUG RESISTANCE; DRUG RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SOLID TUMOR;

DRUG RESISTANCE; HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; NEOPLASTIC STEM CELLS; PHARMACOGENETICS;

EID: 84934438046     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-748-8_19     Document Type: Article

References (113)

1. The Case for Personalized Medicine, 3rd Edition (2011) Personalized medicine coalition. www.personalizedmedicinecoalition. org/sites/default/fi les/fi les/Case-for- PM-3rd-edition.pdf
2. Sorlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874
3. Sherman S, Pletcher BA, Driscoll DA. (2005) Fragile X syndrome: Diagnostic and carrier testing. Genet Med 7:584-587
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
5. Romond EH, Perez EA, Bryant J, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
6. Shuldiner AR, O'Connell JR, Bliden KP, et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical effi cacy of clopidogrel therapy. JAMA 302:849-857
7. Rukov JL, Wilentzik R, Jaffe I, et al. (2013) Pharmaco-miR: Linking microRNAs and drug effects. Brief Bioinform Jan 31. [Epub ahead of print]
8. Foekens JA, Sieuwerts AM, Smid M, et al. (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 105:13021-13026
9. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, et al. (2011) MicroRNA-30c expression level is an independent predictor of clinical benefi t of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 127:43-51
10. Buffa FM, Camps C, Winchester L, et al. (2011) microRNA associated progression pathways and potential therapeutic targets identifi ed by integrated mRNA and microRNA expression profi ling in breast cancer. Cancer Res 71(17):5635-5645
11. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA, Stathopoulos EN. (2011) MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 10:507-517
12. Gong C, Yao Y, Wang Y, et al. (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 286:19127-19137
13. Qian B, Katsaros D, Lu L, et al. (2009) High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res Treat 117:131-140
14. Yan LX, Huang XF, Shao Q, et al. (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14:2348-2360
15. Sempere LF, Christensen M, Silahtaroglu A, et al. (2007) Altered microRNA expression confi ned to specifi c epithelial cell subpopulations in breast cancer. Cancer Res 67:11612-11620
16. Rothe F, Ignatiadis M, Chaboteaux C, et al. (2011) Global MicroRNA expression profi ling identifi es miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 6:e20980
17. Camps C, Buffa FM, Colella S, et al. (2008) hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14:1340-1348
18. Schepeler T, Reinert JT, Ostenfeld MS, et al. (2008) Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68:6416-6424
19. Lanza G, Ferracin M, Gafa R, et al. (2007) mRNA/microRNA gene expression profi le in microsatellite unstable colorectal cancer. Mol Cancer 6:54
20. Drebber U, Lay M, Wedemeyer I, et al. (2011) Altered levels of the onco-microRNA 21 and the tumor suppressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol 39:409-415
21. Nielsen BS, Jorgensen S, Fog JU, et al. (2011) High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 28:27-38
22. Kulda V, Pesta M, Topolcan O, et al. (2010) Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet 200:154-160
23. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. (2010) Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 79:313-320
24. Schetter AJ, Leung SY, Sohn JJ, et al. (2008) MicroRNA expression profi les associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425-436
25. Landi MT, Zhao Y, Rotunno M, et al. (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16:430-441
26. Yu SL, Chen HY, Chang GC, et al. (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13:48-57
27. Raponi M, Dossey L, Jatkoe T, et al. (2009) MicroRNA classifi ers for predicting prognosis of squamous cell lung cancer. Cancer Res 69:5776-5783
28. Takamizawa J, Konishi H, Yanagisawa K, et al. (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753-3756
29. Yanaihara N, Caplen N, Bowman E, et al. (2006) Unique microRNA molecular profi les in lung cancer diagnosis and prognosis. Cancer Cell 9:189-198
30. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. (2008) Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-Time RT-PCR. Clin Chem 54:1696-1704
31. Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y. (2011) miR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J. Cancer Res. Clin Oncol 137:557-566
32. Gallardo E, Navarro A, Vinolas N, et al. (2009) miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30:1903-1909
33. Lebanony D, Benjamin H, Gilad S, et al. (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27:2030-2037
34. Fassina A, Cappellesso R, Fassan M. (2011) Classifi cation of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profi ling. Chest 140:1305-1311. doi: 10.1378/chest.11-0708
35. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. (2010) Accurate classifi cation of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 16:610-619
36. Calin GA, Croce CM. (2006) microRNA signatures in human cancers. Nature 6(11):857-866
37. Zheng T, Wang J, Chen X, Liu L. (2009) Role of microRNA in anticancer drug resistance. Int J Cancer 126(1):2-10
38. van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. (2010) MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 42(8):1282-1290
39. Mishra PJ, Bertino Jr. (2009) microRNA polymorphisms: The future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10(3):399-416
40. Fojo T. (2007) Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplifi cation of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 10(1-2):59-67
41. Tsang WP, Kwok TT. (2008) Let-7a microRNA suppresses therapeutics induced cancer cell death by targeting caspase-3. Apoptosis 13(10): 1215-1222
42. Pothof J, Verkaik NS, van IJcken W, et al. (2009) MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. EMBO J 28(14):2090-2099
43. Nasser MW, Datta J, Nuovo G, et al. (2008) Down-regulation of microRNA-1 (mir-1) in lung cancer: Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by mir-1. J Biol Chem 283(48):33394-33405
44. Wang F, Sun GP, Zou YF, Hao JQ, et al. (2012) MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark 11:259-267
45. Li Z, Hu S, Wang J, et al. (2010) MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in ovarian cancer cells. Gynecol Oncol 119(1):125-130
46. Zhu H, Wu H, Liu X, et al. (2008) Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 76(5):582-588
47. Meng F, Henson R, Lang M, et al. (2006) Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130(7):2113-2129
48. Giovannetti E, Funel N, Peters GJ, et al. (2010) microRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70(11):4528-4538
49. Li J, Huang H, Sun L, et al. (2009) MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15(12):3998-4008
50. Si ML, Zhu S, Wu H, et al. (2007) miR-21-mediated tumor growth. Oncogene 26(9): 2799-2803
51. Corsten MF, Miranda R, Kasmieh R, et al. (2007) microRNA-21 knockdown disrupts glioma in vivo and displays synergistic cytotoxicity with neural precursor cell-delivered S-TRAIL in human gliomas. Cancer Res 67(19):8994-9000
52. Shi L, Chen C, Yang J, et al. (2010) MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352:255-264
53. Gu J, Zhu X, Li Y, et al. (2011) miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol 28(1):211-218
54. Li Y, Zhu X, Gu J, et al. (2010) Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis. Hematology 15(4):215-221
55. Ryan BM, Robles AI, Harris CC. (2010) Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer 10(6):389-402
56. Duan R, Pak C, Jin P. (2007) Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet 16(9):1124-1131
57. Passetti F, Ferreira CG, Costa FF. (2009) The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J 9(1):1-13
58. Tchatchou S, Jung A, Hemminki K, et al. (2009) A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis 30(1):59-64
59. To KK, Zhan Z, Litman T, Bates SE. (2008) Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 28(17):5147-5161
60. Boni V, Zarate R, Villa JC, et al. (2011) Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fl uorouracil and irinotecan. Pharmacogenomics J 11:429-436
61. Reya T, Morrison SJ, Clarke MF, et al. (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105-111
62. Bommer GT, Gerin I, Feng Y, et al. (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17(15):1298-1307
63. Xia HF, He TZ, Liu CM, et al. (2009) MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem 23(4-6):347-358
64. Du L, Pertsemlidis A. (2010) MicroRNAs and lung cancer: Tumors and 22-mers. Cancer Metastasis Rev 29:109-122
65. Song B, Wang Y, Xi Y, et al. (2009) Mechanism of chemoresistance mediated by mir-140 in human osteosarcoma and colon cancer cells. Oncogene 28(46):4065-4074
66. Zou GM. (2008) Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. J Cell Physiol 217(3):598-604
67. Jin L, Hope KJ, Zhai Q, et al. (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167-1174
68. Riccioni R, Dupuis ML, Bernabei M, et al. (2010) The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 45(1):86-92
69. Wang Z, Li Y, Ahmad A, et al. (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13(4-5):109-118
70. Aboody KS, Najbauer J, Danks MK. (2008) Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15(10): 739-752
71. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA. (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137:1032-1046
72. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201
73. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. (2005) Silencing of microRNAs in vivo with antagomirs. Nature 438:685-689
74. Krutzfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, Manoharan M, Stoffel M. (2007) Specifi city, duplex degradation and subcellular localization of anatagomirs. Nucleic Acids Res 35:2885-2892
75. Fabani MM, Gait MJ. (2008) miR-122 targeting with LNA/20-O-methyl oligonucleotide mixers, peptide nucleotides (PNA) and PNApeptide conjugates. RNA 14:336-346
76. Fabani MM, Abreu-Goodger C, Williams D, Lyons PA, Torres AG, Smith KGC, Enright AJ, Gait MJ, Vigorito E. (2010) Effi cient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res 38:4466-4475
77. Koshkin AA, Rajwanshi VK, Wengel J. (1998) Novel convenient synthesys of LNA [2.2.1] bicycle nucleotides. Tetrahedron Lett 39:4381-4384
78. Orom UA, Kaupinnen S, Lund AH. (2006) LNA-modifi ed oligonucleotides mediate specifi c inhibition of microRNA function. Gene 372:137-141
79. Thomas JR, Hergenrother PJ. (2008) Targeting RNA with small molecules. Chem Rev 108:1171-1224
80. Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A. (2008) Small-molecule inhibitors of microRNA miR-21 function. Angew Chem Int Ed 47:7482-7484
81. Zhang S, Chen L, Jung EJ, Calin GA. (2010) Targeting microRNAs with small molecules: From dream to reality. Clin Pharmacol Ther 87:754-758
82. Ebert MS, Sharp PA. (2010) MicroRNA sponges: Progress and possibilities. RNA 16:2043-2050
83. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson E, Bell GW, Teruya-Feldstein J, Weinberg RA. (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28:341-347
84. Chen Y, Zhu X, Zhang X, Liu B, Huang L. (2010) Nanoparticles modifi ed with tumor targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther 18:1650-1656
85. Shi SJ, Zhong ZR, Liu J, Zhang ZR, Sun X, Gong T. (2011) Solid lipid nanoparticles loaded with anti-microRNA oligonuleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharm Res 29:97-109
86. Liu XQ, Song WJ, Sun TM, Zhang PZ, Wang J. (2010) Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using Crgd functionalized nanoparticles. Mol Pharm 8:250-259
87. Bader AG, Brown D, Winkler M. (2010) The promise of microRNA replacement therapy. Cancer Res 70:7027-7030
88. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, Kosaka N, Kawamata M, Kelnar K, Bader AG, Brown D, Ochiya T. (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18:181-187
89. Wu Z, Asokan A, Samulski RJ. (2006) Adenoassociated virus serotypes: Vector toolkit for human gene therapy. Mol Ther 14:316-327
90. Kota J, Chivukula RR, O'Donnell KA. (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005-1017
91. Volinia S, Calin GA, Liu CG, et al. (2006) A microRNA expression signature of human solid tumors defi nes cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261
92. Lin PY, Yu SL, Yang PC. (2010) MicroRNA in lung cancer. Br J Cancer 103:1144-1148
93. Yendamuri S, Kratzke R. (2011) MicroRNA biomarkers in lung cancer: MiRacle or quag-MiRe? Transl Res 157:209-215
94. Iorio MV, Ferracin M, Liu CG, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065-7070
95. Andorfer CA, Necela BM, Thompson EA, Perez EA. (2011) MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med 17:313-319
96. Le QJ, Caldas C. (2010) Micro-RNAs and breast cancer. Mol Oncol 4:230-241
97. Fu SW, Chen L, Man YG. (2011) miRNA biomarkers in breast cancer detection and management. J Cancer 2:116-122
98. Luo X, Burwinkel B, Tao S, Brenner H. (2011) MicroRNA signatures: Novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev 20:1272-1286
99. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. (2012) Candidate microRNA biomarkers in human colorectal cancer: Systematic review profi ling studies and experimental validation. Int J Cancer 130:2077-2087. doi: 10.1002/ ijc.26232
100. Solmi R, Lauriola M, Francesconi M, et al. (2008) Displayed correlation between gene expression profi les and submicroscopic alterations in response to cetuximab, gefi tinib and EGF in human colon cancer cell lines. BMC Cancer 8:227
101. Ragusa M, Majorana A, Statello L, et al. (2010) Specifi c alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 9:3396-3409
102. Zhang W, Winder T, Ning Y, et al. (2011) A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-Type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 22:104-109
103. Graziano F, Canestrari E, Loupakis F, et al. (2010) Genetic modulation of the let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab- irinotecan. Pharmacogenomics J 10:458-464
104. Read ML, Spice R, Parker AL, Mir S, Logan A. (2005) 12th annual congress of the European society of gene therapy. Expert Opin Biol Ther 5:137-141
105. Weiss GJ, Bemis LT, Nakajima E, et al. (2008) EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefi tinib and EGFR expression in cell lines. Ann Oncol 19:1053-1059
106. Rai K, Takigawa N, Ito S, et al. (2011) Liposomal delivery of microRNA-7-expressing plasmid overcomes epidermal growth factor receptortyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther 10(9):1720-1727
107. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284:5731-5741
108. Ferracin M, Pedriali M, Veronese A, et al. (2011) MicroRNA profi ling for the identifi cation of cancers with unknown primary tissueof-origin. J Pathol 225(1):43-45
109. Varadhachary GR, Spector Y, Abbruzzese JL, et al. (2011) Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17:4063-4070
110. Schwarzenbach H, Hoon DS, Pantel K. (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426-437
111. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. (2011) Diagnostic applications of cell-free and circulating tumor cell-Associated miRNAs in cancer patients. Expert Rev Mol Diagn 11:259-275
112. Brase JC, Wuttig D, Kuner R, Sultmann H. (2010) Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9:306
113. Scholer N, Langer C, Dohner H, Buske C, Kuchenbauer F. (2010) Serum microRNAs as a novel class of biomarkers: A comprehensive review of the literature. Exp Hematol 38: 1126-1130